Dr. Raval is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5801 Tinnin Rd NW
Los Ranchos, NM 87107Phone+1 919-618-3621
Summary
- Dr. Jay Raval is a pathologist in Albuquerque, NM and is Director of Transfusion Medicine and
Therapeutic Pathology at the University of New Mexico. He received his medical degree from University of North Carolina at Chapel Hill School of Medicine, received post-graduate training at the University of Pittsburgh Medical Center (UPMC), and has been in practice for 11 years. He specializes in blood banking, transfusion medicine, apheresis medicine, and cellular therapies.
Education & Training
- UPMC Medical Education/Institute for Transfusion MedicineFellowship, Blood Banking/Transfusion Medicine, 2010 - 2011
- UPMC Medical EducationResidency, Pathology-Anatomic and Clinical, 2007 - 2010
- UPMC Medical Education (Pittsburgh)Residency, Surgery, 2006 - 2007
- University of North Carolina at Chapel Hill School of MedicineClass of 2006
Certifications & Licensure
- VT State Medical License 2024 - 2026
- NM State Medical License 2018 - 2025
- NC State Medical License 2012 - 2020
- PA State Medical License 2009 - 2012
- American Board of Pathology Pathology - Clinical
- American Board of Pathology Blood Banking/Transfusion Medicine
Publications & Presentations
PubMed
- 158 citationsEarly Outpatient Treatment for Covid-19 with Convalescent Plasma.David J Sullivan, Kelly A Gebo, Shmuel Shoham, Evan M Bloch, Bryan Lau
The New England Journal of Medicine. 2022-05-05 - 20 citationsTherapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence.Tina S. Ipe, Adeola R. Davis, Jay S. Raval
Frontiers in Neurology. 2021-08-31 - 9 citationsEarly antibody treatment, inflammation, and risk of post-COVID conditions.Kelly A Gebo, Sonya L Heath, Yuriko Fukuta, Xianming Zhu, Sheriza Baksh
Mbio. 2023-10-31
Journal Articles
- ADAMTS13: Origins, Applications, and ProspectsBrian S Zuckerbraun, Matthew D Neal, Jay S Raval, Mitchell R Dyer, Transfusion
Abstracts/Posters
- African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic PurpuraJay S Raval, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Prolonged Circulation of Ultra-Large Von Willebrand Factor and a Reduction in ADAMTS13 Activity Promotes Microvascular Disease Following Traumatic InjuryJay S Raval, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian PopulationsJay S Raval, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: